Orphazyme finds path forward for Niemann-Pick therapy in subgroup data

Orphazyme A/S (CSE:ORPHA) gained DKK15 (35%) to DKK58.50 on Wednesday after it said arimoclomol significantly reduced disease progression in a pair of predefined

Read the full 235 word article

User Sign In